Arizona Firefighters Are Eating Psilocybin Chocolates for PTSD. The FDA Just Decided to Take It Seriously.

In a converted lab in Scottsdale, more than 50 police officers and upwards of 280 firefighters have unwrapped foil-covered chocolates laced with psilocybin, the compound in “magic mushrooms” that alters perception and mood, and eaten them under medical supervision as a treatment for PTSD, the lingering trauma-based anxiety and flashbacks that come from repeatedly seeing the worst day of someone else’s life. The trial belongs to Dr. Sue Sisley’s Scottsdale Research Institute, which holds the only DEA- and FDA-cleared license in the country to actually grow whole psilocybin mushroom spores for clinical research, not just study a synthetic pill version of the drug. The first round of dosing wraps this August, funded in part by $5 million the Arizona legislature set aside for whole-mushroom research in FY2024 — a state government paying to study a Schedule I drug most of its own police force could still be arrested for possessing. InvestigateTV reported the details in April.

Psilocybin didn’t get safer in the last five years. The government just stopped pretending it wasn’t medicine.

That pretending has a start date. In 1970, Congress placed psilocybin in Schedule I of the Controlled Substances Act — the category legally defined as having “no accepted medical use” and the highest potential for abuse, the same bucket as heroin. It didn’t matter that psychiatrists in the 1950s and ’60s had already published hundreds of papers on psychedelics for depression, alcoholism, and end-of-life anxiety. Schedule I made that research nearly impossible to fund, get approved, or publish for the next five decades: no DEA license, no study; no study, no data; no data, no case to reschedule it. The freeze wasn’t a scientific finding. It was a paperwork classification that outlived the politics that created it, and it is only now, in the mid-2020s, visibly thawing.

You can see the thaw in the size of the newest data. Compass Pathways, a drug company running synthetic psilocybin through the FDA approval pipeline, just finished its second Phase 3 trial — the last and largest stage of testing before a drug company can ask the FDA to approve a medicine for the whole country — on 581 people with depression that hadn’t responded to other treatments. Patients who got a 25-milligram dose of the company’s synthetic psilocybin, COMP360, scored 3.8 points lower on a 60-point depression severity scale than patients who got a token 1-milligram dose, a statistically significant gap that held up six months after just one or two dosing sessions. Put plainly: over a third of the people on the real dose saw their depression drop by a quarter or more, from one or two guided sessions, months after the drug had left their system. Compass Pathways reported the results in February — read it knowing it’s the company’s own press release about its own drug, not an independent replication, and weigh it accordingly.

The federal government noticed anyway. After President Trump signed an executive order on psychedelics in April, the FDA handed out “priority review vouchers” to three psychedelic drug programs at once: Compass Pathways’ psilocybin for treatment-resistant depression, the nonprofit Usona Institute’s psilocybin for major depressive disorder, and Transcend Therapeutics’ MDMA-like compound for PTSD. A priority voucher compresses the FDA’s decision window from the usual 10 to 12 months down to roughly one or two — the difference between a drug reaching pharmacies next year or sometime after 2030. STAT News broke the story the same week the Arizona coverage ran, and the timing wasn’t a coincidence so much as a signal: after fifty years of Schedule I, three separate federal and state institutions moved on psilocybin inside the same month.

There’s a fourth data point, and it’s the one nobody was collecting until now. UC Berkeley’s Center for the Science of Psychedelics launched a study called PLASTICITY this June, giving synthetic psilocybin doses ranging from 1 to 30 milligrams to healthy adults aged 60 to 85 and scanning their brains before, one week after, and one month after dosing to track memory, perception, and brain structure. The reason that’s news: a 2024 review found older adults made up just 1.4% of participants across every modern psychedelics study ever run. Every dosing protocol, every safety assumption, every claim about what psilocybin does to a human brain has been built almost entirely on people under 60. Berkeley’s researchers are trying to find out whether a drug this promising for depression and PTSD does anything different — protective or risky — to a brain that’s spent six more decades on earth than the ones it’s mostly been tested on.

The reason that’s news: a 2024 review found older adults made up just 1.4% of participants across every modern psychedelics study ever run.

If you’re in recovery, you’ve probably already sorted psilocybin into one of two bins: a drug someone handed you at a party that you don’t want dredged back up, or a thing you’ve read about online that sounds like it might finally touch the depression or trauma that outlasted your sobriety. Both reactions are reasonable, and neither one should be settled by a state legislature’s press release or a drug company’s earnings call. What’s true is narrower and more useful: under strict medical supervision, at controlled doses, with trained clinicians in the room, psilocybin is producing measurable results in people who’ve tried nearly everything else for PTSD and treatment-resistant depression. What’s also true is that none of this is a green light to self-treat, and a guided clinical dose bears about as much resemblance to a street mushroom trip as a surgical anesthetic bears to a bottle of vodka. A therapist trained in psychedelic-assisted therapy is doing something structurally different from a friend handing you a baggie at a party — the setting, the screening, and the integration work afterward are most of what the clinical trials are actually testing, not just the molecule.

None of this happened because the drug changed. Psilocybin in 2026 is chemically identical to psilocybin in 1970, the year Congress decided it had no medical use and stopped almost all legitimate research on it for two generations of scientists, patients, and clinicians who never got to ask the question properly. What changed is that a state legislature, a drug company, a federal agency, and a public university all decided in the same year that the fifty-year-old answer was wrong, and they’re now racing each other to prove it with better data than the last guy. For readers tracking the broader psychedelics and empathogens landscape, this is the year the regulatory dam actually started to move, not just the year everyone talked about it moving.

Sisley’s firefighters didn’t wait for the paperwork to catch up to them — they enrolled in a trial for a drug the federal government still calls as dangerous as heroin, because the alternative was living with PTSD that hadn’t responded to anything else. The Phase 3 numbers, the priority vouchers, and the Berkeley scans are the rest of the system finally catching up to a decision those firefighters had already made for themselves.